A Lancet Commission report projects a concerning rise in adolescent obesity, estimating nearly 500 million cases by 2030. This surge, particularly in high-income nations, Latin America ...

All figures are at CER. Novo Nordisk also highlighted the completion of its REDEFINE 2 trial for CagriSema, its next-generation obesity drug. The treatment delivered a 15.7% weight reduction.

Notably, its experimental drug CagriSema has fallen short of market expectations, leading to a decline in share price despite the treatment meeting primary endpoints in studies. Meanwhile, current GLP ...

Within R&D, Novo Nordisk completed the REDEFINE 2 trial, where CagriSema demonstrated superior weight loss of 15.7% in adults with obesity or overweight and type 2 diabetes. Novo Nordisk still ...

Another challenge for Novo Nordisk has been disappointing trial results for CagriSema, its next-generation obesity treatment. Despite the setbacks, Jørgensen had remained publicly confident in ...

Novo Nordisk is also developing a new drug, CagriSema, designed to be injected less frequently, but its clinical trial results have disappointed investors because participants did not lose as much ...

However, the company has struggled to shake negative sentiment following a series of disappointing trial results for its next-generation obesity drug candidate CagriSema. Novo Nordisk confirmed ...